Flutamide
- Generic Name
- Flutamide
- Brand Names
- Eulexin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H11F3N2O3
- CAS Number
- 13311-84-7
- Unique Ingredient Identifier
- 76W6J0943E
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
- Associated Conditions
- Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate
- Associated Therapies
- -
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Taro Iguchi, MD, PHD
- Target Recruit Count
- 104
- Registration Number
- NCT02346578
- Locations
- 🇯🇵
Osaka City University Graduate School of Medicine, Osaka, Japan
Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 45
- Registration Number
- NCT01889199
- Locations
- 🇺🇸
UCaliforniaLA, Los Angeles, California, United States
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 310
- Registration Number
- NCT01786265
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
- Conditions
- Interventions
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 4
- Registration Number
- NCT01428193
- Locations
- 🇺🇸
Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 273
- Registration Number
- NCT01122121
- Locations
- 🇫🇷
Clinique Mutualiste, Saint-etienne, France
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 311
- Registration Number
- NCT01011751
- Locations
- 🇫🇷
Professor Jacques IRANI, Poitiers, France
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 1538
- Registration Number
- NCT00936390
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 72
- Registration Number
- NCT00930228
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 341
- Registration Number
- NCT00817739
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 1322
- Registration Number
- NCT00769548
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.